Detail akcie PureTech Health online

Business Summary: PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Puretech Health PLC revenues decreased 55% to $3.2M. Net loss applicable to common stockholders decreased 12% to $25M. Revenues reflect Controlled Founded En segment decrease of 84% to $750K, Internal segment decrease of 63% to $673K. Lower net loss reflects FV Adjustments of Financial Investments increase from $59M (expense) to $7.8M (income).